UCB
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, and Otsuka. The company was founded in 1928 and is headquartered in Brussels, Belgium. Show More...
-
Website http://www.ucb.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 124.55 EUR
-
Last Updated 26-04-2024
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR 0.56 1.32 1.39 0.88 1.1 3.25 2.76 4.0 4.24 4.23 4.23 Dividends EUR 1.92 0.98 1.0 1.02 1.04 1.06 1.1 1.15 1.18 1.21 1.21 Payout Ratio % * 336.8 122.5 75.1 95.3 68.4 93.8 61.8 32.5 25.5 34.9 28.7 Shares Mil 184.0 192.0 179.0 193.0 190.0 192.0 188.0 188.0 188.0 187.0 187.0 Book Value Per Share * EUR 25.47 26.96 25.9 25.08 25.18 28.04 27.43 29.82 31.75 34.38 37.33 Free Cash Flow Per Share * EUR 2.32 1.79 0.7 -0.83 0.95 1.62 -0.3 3.31 3.76 3.62 Return on Assets % 1.14 2.59 2.76 2.15 2.08 5.9 4.91 7.48 7.83 7.34 7.34 Financial Leverage (Average) 1.95 1.9 2.04 2.15 2.03 1.93 1.83 1.7 1.67 1.57 1.57 Return on Equity % 2.29 4.99 5.44 4.5 4.35 11.67 9.24 13.21 13.2 11.87 11.87 Return on Invested Capital % 3.41 5.21 5.66 4.16 4.13 9.1 7.43 10.79 11.02 10.27 10.27 Interest Coverage 1.1 2.12 2.68 2.76 1.77 5.95 9.78 18.64 17.37 17.0 17.0 Current Ratio 0.93 1.06 1.01 1.04 1.07 0.93 0.96 1.37 1.32 1.38 1.38 Quick Ratio 0.68 0.72 0.6 0.7 0.49 0.67 0.64 0.91 0.92 0.92 0.92 Debt/Equity 0.38 0.37 0.41 0.44 0.35 0.28 0.28 0.26 0.21 0.14 0.14